Strengthening cardiac therapy pipelines using human pluripotent stem cell-derived cardiomyocytes
Kavita Raniga, Aishah Nasir, Nguyen T.N. Vo, Ravi Vaidyanathan, Sarah Dickerson, Simon Hilcove, Diogo Mosqueira, Gary R. Mirams, Peter Clements, Ryan Hicks, Amy Pointon, W. Stebbeds, Jo Francis, Chris Denning
Abstract
Advances in hiPSC isolation and reprogramming and hPSC-CM differentiation have prompted their therapeutic application and utilization for evaluating potential cardiovascular safety liabilities. In this perspective, we showcase key efforts toward the large-scale production of hiPSC-CMs, implementation of hiPSC-CMs in industry settings, and recent clinical applications of this technology. The key observations are a need for traceable gender and ethnically diverse hiPSC lines, approaches to reduce cost of scale-up, accessible clinical trial datasets, and transparent guidelines surrounding the safety and efficacy of hiPSC-based therapies.